Hepatitis A antibodies in attenders of London travel clinics: Cost‐benefit of screening prior to hepatitis A immunisation

Abstract

The seroprevalence of hepatitis A antibodies in travellers attending London Travel Clinics increases with age and screening may eliminate the need for vaccination at present for approximately 40% of adults. The duration of protection by current hepatitis A vaccine(s) is still to be established.